|Baxter Launches New AK 98 Hemodialysis System Designed to Help Providers Reach Treatment Goals|
|View printer-friendly version|
The AK 98 system can be used to deliver HDx enabled by THERANOVA, Baxter’s latest hemodialysis therapy that provides high performance treatments with integration into existing healthcare infrastructure. Due to kidney failure, people with end-stage renal disease retain harmful toxins in their blood. During HD therapy, blood is passed through a dialyzer, which acts as the artificial kidney to filter toxins from the blood.
“We designed our new AK 98 system specifically to help dialysis
providers minimize the operational challenges associated with
The AK 98 system can now be connected to the dialysis provider’s central IT network, allowing seamless management and integration of clinic and treatment information. During treatment set-up, the hemodialysis prescription is sent to the AK 98 system from the provider’s central IT network. Once treatment is concluded, the encrypted data is transmitted back to the provider’s network, where it is secured and stored. Treatment data is then cleared from the AK 98 system.
The AK 98 system features new blood lines, which work alongside Baxter’s smallest dialyzers, to help providers treat low weight patients, whose lower blood volumes require specialized equipment for effective HD treatment.
The AK 98 system, which first launched in 2015, is available in many
About HDx enabled by THERANOVA
Baxter’s HDx therapy, or expanded hemodialysis, is enabled by the
THERANOVA dialyzer, an innovative membrane that provides the opportunity
for HDF performance and beyond. HDx enabled by THERANOVA effectively
targets large middle molecules not efficiently removed by currently
available dialysis treatments. In
a study published in Nephrology Dialysis Transplantation1,
researchers found that the THERANOVA dialyzer removes a wide range of
middle molecules more effectively than FX CorDiax high-flux dialyzer,
and can exceed the performance of high-volume HDF for large solutes,
with moderate albumin removal.1 THERANOVA dialyzers are
indicated for treatment of chronic and acute renal failure by
hemodialysis. HDx enabled by THERANOVA therapy is available in
Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
This release includes forward-looking statements concerning the AK 98
system and the THERANOVA dialyzer, including potential benefits
associated with their use. The statements are based on assumptions about
many important factors, including the following, which could cause
actual results to differ materially from those in the forward-looking
statements: satisfaction of regulatory and other requirements; actions
of regulatory bodies and other governmental authorities; product
quality, manufacturing or supply, or patient safety issues; changes in
law and regulations; breaches or failures of the company’s information
technology systems; and other risks identified in Baxter's most recent
filing on Form 10-K and other
Baxter, AK 98 and Theranova are trademarks of
1 Kirsch A. H., et al. Performance of hemodialysis with novel
medium cut-off dialyzers. Nephrol Dial Transplant (2016)
Baxter International Inc.